Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency

N Engl J Med. 2004 Feb 26;350(9):913-22. doi: 10.1056/NEJMra032207.
No abstract available

Publication types

  • Review

MeSH terms

  • Adaptor Proteins, Signal Transducing
  • Animals
  • DNA-Binding Proteins / genetics*
  • Gene Expression Regulation
  • Gene Expression Regulation, Leukemic*
  • Genetic Diseases, X-Linked / genetics
  • Genetic Diseases, X-Linked / therapy
  • Genetic Therapy / adverse effects*
  • Humans
  • LIM Domain Proteins
  • Leukemia, T-Cell / genetics
  • Metalloproteins / genetics*
  • Oncogenes*
  • Proto-Oncogene Proteins
  • Receptors, Interleukin-2 / genetics
  • Retroviridae / genetics
  • Retroviridae / physiology
  • Severe Combined Immunodeficiency / genetics
  • Severe Combined Immunodeficiency / therapy*
  • T-Lymphocytes*
  • Translocation, Genetic
  • Virus Activation

Substances

  • Adaptor Proteins, Signal Transducing
  • DNA-Binding Proteins
  • LIM Domain Proteins
  • LMO2 protein, human
  • Metalloproteins
  • Proto-Oncogene Proteins
  • Receptors, Interleukin-2